Literature DB >> 15054086

Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?

Anita Sidhu1, Christophe Wersinger, Philippe Vernier.   

Abstract

alpha-Synuclein is a key component of the pathological process of neurodegeneration in Parkinson's disease. Although its contributions to normal physiological conditions remain elusive, converging observations suggest that a primary function of this protein in dopaminergic neurons may be the regulation of dopamine content and synaptic tone at the synapse. We review here cumulative evidence that demonstrates the participation of alpha-synuclein in the life cycle of dopamine from its synthesis, storage, release, and reuptake. The regulatory role of alpha-synuclein on dopamine metabolism is assessed by discussing the experimental evidence supporting each of these observations in the healthy physiological maintenance of dopaminergic neurons, as well as showing how disruption of these events can initiate the observed neurotoxicity of alpha-synuclein and the genesis of the degenerative processes associated with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15054086     DOI: 10.1096/fj.03-1112rev

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  54 in total

1.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.

Authors:  Pablo Garcia-Reitböck; Oleg Anichtchik; Arianna Bellucci; Mariangela Iovino; Chiara Ballini; Elena Fineberg; Bernardino Ghetti; Laura Della Corte; PierFranco Spano; George K Tofaris; Michel Goedert; Maria Grazia Spillantini
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

2.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 3.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

4.  Membrane insertion exacerbates the α-Synuclein-Cu(II) dopamine oxidase activity: Metallothionein-3 targets and silences all α-synuclein-Cu(II) complexes.

Authors:  Jenifer S Calvo; Neha V Mulpuri; Alex Dao; Nabeeha K Qazi; Gabriele Meloni
Journal:  Free Radic Biol Med       Date:  2020-07-23       Impact factor: 7.376

5.  Secondary structure and dynamics of micelle bound beta- and gamma-synuclein.

Authors:  Yoon-Hui Sung; David Eliezer
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

6.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.

Authors:  Martin Lundblad; Mickael Decressac; Bengt Mattsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

7.  Partial regulation of serotonin transporter function by gamma-synuclein.

Authors:  Christophe Wersinger; Anita Sidhu
Journal:  Neurosci Lett       Date:  2009-02-21       Impact factor: 3.046

8.  RNA interference mediated silencing of alpha-synuclein in MN9D cells and its effects on cell viability.

Authors:  Dong-Mei Liu; Ling Jin; Hao Wang; Huan-Ying Zhao; Chun-Li Zhao; Hui Yang
Journal:  Neurosci Bull       Date:  2008-04       Impact factor: 5.203

9.  Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway.

Authors:  Nanping Wu; Prasad R Joshi; Carlos Cepeda; Eliezer Masliah; Michael S Levine
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

10.  Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.